Former Tennessee US senator, heart and lung transplant surgeon, and healthcare entrepreneur brings dynamic expertise to the OneOncology national network.
OneOncology announced the election of former US Senate Majority Leader Bill Frist to its board of directors. Frist brings unparalleled insights to OneOncology as a nationally-acclaimed thoracic surgeon, designing effective, bipartisan healthcare policy, and building patient-centered healthcare companies.
“We are honored to have Senator Frist as part of our organization,” said Tracy L. Bahl, OneOncology president and chief executive. “Senator Frist will add immeasurable value to OneOncology across multiple dimensions. As a surgeon, he reinforces our commitment to building a physician-led organization, as the former Senate Majority Leader, his counsel will help our practices navigate the evolving regulatory environment, and as an entrepreneur, he will lend incredible insight into technology-powered cancer care delivery—all of which support a differentiated patient experience across the entire continuum of care.”
Frist believes technology enables the most comprehensive and compassionate care experience for patients and their families. As a OneOncology board director, Frist said he will focus on helping OneOncology leverage its technology and data platform to drive its physician-led and patient-centric model.
“By establishing a physician-governed organization, every oncologist in our network can provide their patients with the best care, close to their home,” Frist said. “Through a nationally connected network and technology platform, OneOncology can standardize and share best-in-class treatment protocols, cancer therapies, and clinical trials to offer patients outcomes that at one time were deemed unimaginable.”
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More